Mechanism of polymeric nanoparticle-based drug transport across the blood-brain barrier (BBB)

Journal of Microencapsulation

Volumn 30, Issue 1, 2013, Pages 49-54

  Kreuter, Jörg ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

BBB; Blood brain barrier; Brain delivery; Doxorubicin; Glioblastoma; Nanoparticles; Nerve growth factor

Indexed keywords

ANTIBODY; APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; APOLIPOPROTEIN E; CYANOACRYLATE DERIVATIVE; DOXORUBICIN; INSULIN; LEUCINE ENKEPHALIN[2 DEXTRO ALANINE 6 ARGININE]; LOPERAMIDE; LOW DENSITY LIPOPROTEIN RECEPTOR; NANOPARTICLE; NERVE GROWTH FACTOR; POLOXAMER; POLY(BUTYL CYANOACRYLATE); POLYGLACTIN; POLYMER; POLYSORBATE 80; SCAVENGER RECEPTOR; SUCROSE; TRANSFERRIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BRAIN TISSUE; CANCER SURVIVAL; CELL MEMBRANE; CELL VIABILITY; CONFOCAL LASER MICROSCOPY; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG TRANSPORT; ENDOCYTOSIS; ENDOTHELIUM CELL; GLIOBLASTOMA; NONHUMAN; PROTEIN PROTEIN INTERACTION; SURVIVAL TIME; TRANSCYTOSIS; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; BLOOD-BRAIN BARRIER; DOXORUBICIN; MICE; NANOPARTICLES; NERVE GROWTH FACTOR; POLYMERS;

EID: 84871455407     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2012.692491     Document Type: Article

References (47)

1. Alyautdin R, Gothier D, Petrov V, Kharkevich D, Kreuter J. Analgesic activity of the hexapeptide dalargin adsorbed on the surface of polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles. Eur J Pharm Biopharm, 1995;41:44-8.
2. Alyautdin RN, Petrov VE, Langer K, Berthold A, Kharkevich DA, Kreuter J. Delivery of loperamide across the blood-brain barrier with poly-sorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharm Res, 1997;14:325-8.
3. Alyautdin RN, Reichel A, Löbenberg R, Ramge P, Kreuter J, Begley DJ. Interaction of poly-(butylcyanoacrylate) nanoparticles with the blood-brain barrier in vivo and in vitro. J Drug Target, 2001;9:209-21.
4. Alyautdin RN, Tezikov E, Ramge P, Kharkevich DA, Begley DJ, Kreuter J. Significant entry of tubocurarine into the brain of rats by absorption to polysorbate 80-coated polybutyl-cyanoacrylate nanoparticles: an in situ brain perfusion study. J Microencapsul, 1998;5:67-74.
5. Ambruosi A, Gelperina S, Khalansky AS, Tanski S, Theisen A, Kreuter J. Influence of surfactants, polymer, and doxorubicin loading on the anti-tumour effect of poly(butyl cyanoacrylate) nanoparticles in a rat glioma model. J Microencapsul, 2006;23:582-92.
6. Begley DJ. The blood-brain barrier: Principles for targeting peptides and drugs to the central nervous system. J Pharm Pharmacol, 1996;48:136-46.
7. Begley DJ. Delivery of therapeutic agents to the central nervous system: The problems and possibilities. Pharmacol Therap, 2004;104:29-45.
8. Borchard G, Audus KL, Shi F, Kreuter J. Uptake of surfactant-coated poly(methyl methacrylate)-nanoparticles by bovine brain microvessel endothelial cell monolayers. Int J Pharm, 1994;110:29-35.
9. Brightman M. 1992. Ultrastructure of the brain endothelium. In: Bradbury MWB, ed. Handbook of experimental pharmacology. physiology and pharmacology of the blood-brain barrier, Vol. 103. Berlin, Heidelberg: Springer, pp. 1-22.
10. Cordon-Cardo C, O'Brien JP, Casals D, Rittmann-Grauer L, Biedler JL, Melamed MR, Bertino Jr. Multidrug resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci USA, 1989;86:695-8.
11. Friese A, Seiller E, Quack G, Lorenz B, Kreuter J. Increase of the duration of the anticonvulsive activity of a novel NMDA receptor antagonist using poly(butylcyanoacylate) nanoparticles as a parenteral controlled release system. Eur J Pharm Biopharm, 2000;49:103-9.
12. Gelperina SE, Khalansky AS, Skidan IN, Smirnova ZS, Bobruskin AI, Severin SE, Turowski B, Zanella FE, Kreuter J. Toxicological studies of doxorubicin bound to polysorbate 80-coated poly(butyl cyanoacrylate) nanoparticles in healthy rats and rats with intracranial glioblastoma. Toxicol Lett, 2002;126:131-41.
13. Gelperina S, Maksimenko O, Khalansky A, Vanchugova L, Shipulo E, Abbasova K, Berdiev R, Wohlfart S, Chepurnova N, Kreuter J. Drug delivery to the brain using surfactant-coated poly(lactide-co-glycolide) nanoparticles: Influence of the formulation parameters. Eur J Pharm Biopharm, 2010;74:157-63.
14. Gulyaev AE, Gelperina SE, Skidan IN, Antropov AS, Kivman GYa, Kreuter J. Significant transport of doxorubicin into the brain with polysorbate 80-coated nanoparticles. Pharm Res, 1999;16:1564-6.
15. Hasadsri L, Kreuter J, Hattori H, Iwasaki T, George JM. Functional protein delivery into neurons using polymeric nanoparticles. J Biol Chem, 2009;284:6972-81.
16. Hekmatara T, Bernreuther C, Khalansky AS, Theisen A, Weissenberger J, Gelperina S, Kreuter J, Glatzel M. Efficient systemic therapy of rat glio-blastoma by nanoparticle-bound doxorubicin is due to antiangiogenic effects. Clin Neuropathol, 2009;28:153-64.
17. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev, 2001;47:65-81.
18. Kreuter J. 2006. Nanoparticulate carriers for drug delivery to the brain. In: Torchilin VP, ed. Nanoparticles as drug carriers. London: Imperial College Press, pp. 527-47.
19. Kreuter J, Alyautdin RN, Kharkevich DA, Ivanov AA. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nano-particles). Brain Res, 1995;674:171-4.
20. Kreuter J, Hekmatara T, Dreis S, Vogel T, Gelperina S, Langer K. Covalent attachment of apolipoprotein AI and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain. J Controlled Rel, 2007;118:54-8.
21. Kreuter J, Petrov VE, Kharkevich DA, Alyautdin RN. Influence of the type of surfactant on the analgesic effects induced by the peptide dalargin after its delivery across the blood-brain barrier using surfactant-coated nanoparticles. J Controlled Rel, 1997;49:81-7.
22. Kreuter J, Ramge P, Petrov V, Hamm S, Gelperina SE, Engelhardt B, Alyautdin R, von Briesen H, Begley DJ. Direct evidence that polysorbate 80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drugs to nano-particles. Pharm Res, 2003;20:409-16.
23. Kreuter J, Shamenkov D, Petrov V, Ramge P, Cychutek K, Koch-Brandt C, Alyautdin R. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target, 2002;10:317-25.
24. Kurakhmaeva KB, Djindjikashvili IA, Petrov VE, Balabanyan VU, Voronina TA, Trofimov SS, Kreuter J, Gelperina S, Begley D, Alyautdin RN. Brain targeting of nerve growth factor using poly(butyl cyanoacrylate) nanoparticles. J Drug Target, 2009;17:564-74.
25. Lück M. 1997. Plasmaproteinadsorption als möglicher Schlüsselfaktor für eine kontrollierte Arzneistoffapplikation mit partikulären Trägern. PhD Thesis, Berlin, Freie Universität, pp. 14-24, 137-54.
26. Michaelis K, Hoffmann MM, Dreis S, Herbert E, Alyautdin RN, Michaelis M, Kreuter J, Langer K. Covalent linkage of apolipoprotein E to albumin-nanoparticles strongly enhances drug transport into the brain. J Pharmacol Exp Ther, 2006;317:1246-53.
27. Nerurkar MM, Burto PS, Borchardt RT. The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system. Pharm Res, 1996;13:528-34.
28. Neuwelt EA, Barnett PA. 1989. Blood-brain barrier disruption in the treatment of brain tumors. Animal studies. In: Neuwelt EA, ed. Implications of the blood-brain barrier and its manipulation, Vol. 2. New York: Plenum, pp. 195-217.
29. Olivier J-C, Fenart L, Chauvet R, Pariat C, Cecchelli R, Couet W. Indirect evidence that drug brain targeting using polysorbate 80-coated polybu-tylcyanoacrylate nanoparticles is related to toxicity. Pharm Res, 1999;16:1836-42.
30. Pereverzeva E, Treschalin I, Bodyagin D, Maksimenko O, Kreuter J, Gelperina S. Intravenous tolerance of a nanoparticle-based formulation of doxorubicin in healthy rats. Toxicol Letters, 2008;178:9-19.
31. Pereverzeva E, Treschalin I, Bodyagin D, Maksimenko O, Langer K, Dreis S, Asmussen B, Kreuter J, Gelperina S. Influence of the formulation on the tolerance profile of nanoparticle-bound doxorubicin in healthy rats: Focus on cardio-and testicular toxicity. Int. J. Pharm, 2007;337:346-56.
32. Petri B, Bootz A, Khalansky A, Hekmatara T, Müller R, Uhl R, Kreuter J, Gelperina S. Chemotherapy of brain tumour using doxorubicin bound to surfactant-coated poly(butyl cyanoacrylate) nano-particles: Revisiting the role of surfactants. J Controlled Rel, 2007;117:51-8.
33. Ramge P, Unger RE, Oltrogge JB, Zenker D, Begley D, Kreuter J, von Briesen H. Polysorbate 80-coating enhances uptake of polybutylcyanoa-crylate (PBCA)-nanoparticles by human and bovine primary brain capillary endothelial cells. Europ J Neurosci, 2000;12:1931-40.
34. Sanchez de Juan B, von Briesen H, Gelperina SE, Kreuter J. Cytotoxicity of doxorubicin bound to poly(butyl cyanoacrylate) nanoparticles in rat glioma cell lines using different assays. J Drug Target, 2006;14:614-22.
35. Steiniger SCJ, Kreuter J, Khalansky AS, Skidan IN, Bobruskin AI, Smirnova ZS, Severin SE, Uhl R, Kock M, Geiger KD, et al. Chemotherapy of glioblastoma in rats using doxorubicin-loaded nano-particles. Int J Cancer, 2004;109:759-67.
36. Tahara K, Kato Y, Yamamoto H, Kreuter J, Kawashima Y. Intracellular drug delivery using polysorbate 80-modified poly(D,L-lactide-co-glycolide) nanospheres to glioblastoma cells. J Microencapsul, 2011;28:29-36.
37. Ulbrich K, Hekmatara T, Herbert E, Kreuter J. Transferrin-and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur J Pharm Biopharm, 2009;71:251-6.
38. Ulbrich K, Knobloch T, Kreuter J. Targeting the insulin receptor: Nanoparticles for drug delivery across the blood-brain barrier (BBB). J Drug Target, 2011;19:125-32.
39. Wagner S, Kufleitner J, Zensi A, Dadparvar M, Wien S, Bungert J, Vogel T, Worek F, Kreuter J, von Briesen H. Nanoparticulate transport of oximes over an in vitro blood-brain barrier model. PLoS ONE, 2010;5:e14213.
40. Wohlfart S, Bernreuther C, Khalansky AS, Theisen A, Weissenberger J, Gelperina S, Glatzel M, Kreuter J. Increased numbers of injections of doxorubicin bound to nanoparticles lead to enhanced efficacy against rat glioblastoma 101/8. J Nanoneurosci, 2009;1:144-51.
41. Wohlfart S, Gelperina S, Kreuter J. Transport of drugs across the blood-brain barrier by nanoparticles. J Controlled Rel (e-publ. 2011).
42. Wohlfart S, Khalansky AS, Bernreuther C, Michaelis M, Cinatl J, Glatzel M, Kreuter J. Treatment of glioblastoma with poly(isohexyl cyanoacrylate) nanoparticles. Int J Pharm, 2011b;415:244-51.
43. Wohlfart S, Khalansky AS, Gelperina S, Begley D, Kreuter J. Kinetics of transport of doxorubicin bound to nanoparticles across the blood-brain barrier. J Controlled Rel, 2011a;154:103-7.
44. Wohlfart S, Khalansky AS, Gelperina S, Maksimenko O, Bernreuther C, Glatzel M, Kreuter J. Efficient chemotherapy of rat glioblastoma using doxorubicin-loaded PLGA nanoparticles with different stabilizers. PLoS ONE, 2011c;6:e19121.
45. Woodcock DM, Linsenmeyer ME, Chrojnowski G, Kriegler AB, Nink V, Webster LK, Sawyer WH. Reversal of multidrug resistance by surfactants. Br J Cancer, 1992;66:62-8.
46. Zensi A, Begley D, Pontikis C, Legros C, Mihoreanu L, Büchel C, Kreuter J. Human serum albumin nanoparticles modified with apolipoprotein A-I cross the blood-brain barrier and enter the rodent brain. J Drug Target, 2010;18:842-8.
47. Zensi A, Begley D, Pontikis C, Legros C, Mihoreanu L, Wagner S, Büchel C, von Briesen H, Kreuter J. Albumin nanoparticles targeted with Apo E enter the CNS by transcytosis and are delivered to neurones. J Controlled Rel, 2009;137:78-86.